HCW Biologics Inc. (HCWB) stock
HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.76−0.01 (-1.65%)
Close on Nov 18, 2026Market cap $1.40MP/E –Yield –
HCW Biologics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
HCW Biologics's profit margin for the twelve months ending Jun 30, 2026 was -83.8%. For fiscal 2025 it was -14677.1%, against -1169.7% the year before. The highest annual figure on record is -141.5% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -14677.1% | −13507.4 |
| FY2024 | Dec 31, 2024 | -1169.7% | −290.2 |
| FY2023 | Dec 31, 2023 | -879.5% | −657.9 |
| FY2022 | Dec 31, 2022 | -221.7% | −80.1 |
| FY2020 | Dec 31, 2020 | -141.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -4287.5% | +25143.4 |
| Q1 FY2026 | Mar 31, 2026 | 53.4% | +43427.1 |
| Q4 FY2025 | Dec 31, 2025 | 2662.8% | +3517.3 |
| Q3 FY2025 | Sep 30, 2025 | -29183.2% | −28268.1 |
| Q2 FY2025 | Jun 30, 2025 | -29431.0% | −26961.9 |
| Q1 FY2025 | Mar 31, 2025 | -43373.6% | −42710.8 |
| Q4 FY2024 | Dec 31, 2024 | -854.4% | −47.7 |
| Q3 FY2024 | Sep 30, 2024 | -915.1% | −336.2 |
| Q2 FY2024 | Jun 30, 2024 | -2469.1% | −1778.0 |
| Q1 FY2024 | Mar 31, 2024 | -662.8% | +11444.0 |
| Q4 FY2023 | Dec 31, 2023 | -806.7% | −402.8 |
| Q3 FY2023 | Sep 30, 2023 | -578.9% | −362.5 |
| Q2 FY2023 | Jun 30, 2023 | -691.1% | +82.1 |
| Q1 FY2023 | Mar 31, 2023 | -12106.8% | −12040.8 |
| Q4 FY2022 | Dec 31, 2022 | -403.9% | −454.2 |
| Q3 FY2022 | Sep 30, 2022 | -216.4% | – |
| Q2 FY2022 | Jun 30, 2022 | -773.3% | – |
| Q1 FY2022 | Mar 31, 2022 | -66.0% | – |
| Q4 FY2020 | Dec 31, 2020 | 50.3% | – |
See a number that looks wrong?